Editing
Protein Engineering
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== <span style="color: #FFFFFF;">Understanding</span> == Protein engineering AI accelerates the two core engineering tasks: '''variant optimization''' (improving an existing protein) and '''de novo design''' (creating entirely new proteins). '''Variant effect prediction''': Given a protein sequence and a mutation, predict whether the mutation improves or worsens a desired property. Zero-shot approaches use protein language model log-likelihood β a mutation that the PLM assigns higher probability than the wild-type is more evolutionarily "accepted" and likely functionally tolerable. ESM-2 log-ratios correlate significantly with experimental fitness data (DMS). This enables in silico screening of millions of variants. '''Inverse folding for sequence design''': Given a desired 3D structure (from AlphaFold or experimental data), design sequences that will fold to that structure. ProteinMPNN (Dauparas et al., 2022) is the standard tool β it takes a backbone structure as input and generates sequences compatible with that backbone, achieving experimental success rates of 50β80% for designed sequences. This replaces computationally expensive Rosetta-based design. '''RFDiffusion for de novo backbone generation''': RFDiffusion (Watson et al., 2023) generates novel protein backbone structures by running the diffusion process in the space of protein structures. It can generate binders to arbitrary targets, symmetric assemblies, enzyme active sites, and more β with experimental validation. Combined with ProteinMPNN (RFDiffusion β backbone β ProteinMPNN β sequence β validate), this pipeline has created proteins binding previously undruggable targets. '''Antibody engineering''': Antibodies are the dominant class of biologic drugs (~$250B market). AI systems like AbMap, AntiBERTy, IgLM, and proprietary tools at Absci, Insilico Medicine, and BigHat Biosciences design and optimize antibodies by training on billions of known antibody sequences. They predict binding affinity, developability (manufacturability), and immunogenicity. </div> <div style="background-color: #8B0000; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
Summary:
Please note that all contributions to BloomWiki may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
BloomWiki:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
View history
More
Search
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information